# US 12,601,017 B2 · Molecular detection of novel coronaviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,601,017 B2
- Document ID: US12601017B2
- Status: Granted
- Kind: B2
- Application number: 17/545,818
- Filed: 2021-12-08
- Published: 2022-08-04
- Granted: 2026-04-14
- Earliest claimed: 2021-01-31
- Assignees: The University of Hong Kong
- Applicants: The University of Hong Kong
- Inventors: Leo LM Poon; Malik Peiris; Daniel K.W. Chu
- Web page: https://patentgrep.com/patent/US12601017B2

## CPC

- C12Q 1/701: {Specific hybridization probes}
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Systems for sensitive and accurate detection of sarbecoviruses in samples from human sputum have been established. The systems can rapidly and effectively diagnose patients having suspected coronavirus infections. The systems employ Reverse-Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) to identify and quantify nucleic acids specific to sarbecoviruses within samples from human patients. The systems identify viral RNAs specific for the N and ORF1 genes using a two-step real-time PCR and the SYBR Green detection method. Compositions and methods for reproducibly detecting and quantifying concentrations of sarbecoviruses with a dynamic range of at least seven orders of magnitude (2×10−4-2000 TCID50/reaction) are described. The compositions and methods enable rapid early diagnosis of patients, as well as development of databases of patient viral titres and infectious dosages.

## Claims

### Claim 1

A composition for the detection of SARS-CoV-2 virus N gene comprising PCR primers for amplifying a segment of the SARS-CoV-2 virus N gene comprising nucleotides corresponding to nucleotides 905-923, 894-962, or 872-981 of SEQ ID NO:8.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the PCR primers comprise:
(i) a nucleic acid sequence consisting of SEQ ID NO:4 or a nucleic acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:4, and
(ii) a nucleic acid sequence consisting of SEQ ID NO:5 or a nucleic acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:5.

### Claim 3

A composition for the detection of SARS-COV-2 virus ORF1b gene comprising PCR primers for amplifying a segment of the SARS-COV-2 virus ORF1b gene comprising nucleotides corresponding to nucleotides 18547-18565, 18536-18604, or 18514-18645 of SEQ ID NO:7.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the PCR primers comprise:
(i) a nucleic acid sequence consisting of SEQ ID NO: 1 or a nucleic acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:1, and
(ii) a nucleic acid sequence consisting of SEQ ID NO:2 or a nucleic acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:2.

### Claim 5 (depends on 1)

The composition of claim 1, further comprising a nucleic acid probe having one or more fluorescent reporters, one or more quenchers, or a combination thereof,
wherein the probe is configured to specifically bind to a nucleic acid sequence within SEQ ID NO:8, optionally within nucleotides 905-923, 894-962, or 872-981 of SEQ ID NO:8.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the nucleic acid probe has a nucleic acid sequence consisting of SEQ ID NO:6 or a nucleic acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:6.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising a nucleic acid probe having one or more fluorescent reporters, one or more quenchers, or a combination thereof,
wherein the probe is configured to specifically bind to a nucleic acid sequence within SEQ ID NO:7, optionally within nucleotides 18547-18565, 18536-18604, or 18514-18645 of SEQ ID NO:7.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the nucleic acid probe has a nucleic acid sequence consisting of SEQ ID NO:3 or a nucleic acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:3.

### Claim 9 (depends on 1)

The composition of claim 1 further comprising one or more of a phosphate buffer, a Tris buffer, a potassium salt, a sodium salt, a magnesium salt, an ammonium salt, dATP, dCTP, dGTP, and dTTP, a reverse transcriptase enzyme, and a DNA polymerase enzyme.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the salt is selected from the group consisting of KCl, NaCl, MgCl2, MgSO4, and (NH4)2SO4.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the DNA polymerase is Taq polymerase.

### Claim 12 (depends on 5)

A method of detecting the presence of SARS-COV-2 nucleic acid in an input sample, comprising:
(a) contacting the input sample with the composition of claim 5 under conditions sufficient for amplification of one or more regions of the N gene of SARS-COV-2,
wherein detection of the SARS-COV-2 N gene amplification product indicates the presence of SARS-COV-2 in the input sample.

### Claim 13 (depends on 12)

The method of claim 12, wherein the amplification comprises a reverse transcription quantitative polymerase chain reaction (RT-qPCR).

### Claim 14 (depends on 12)

The method of claim 12, wherein the input sample comprises purified nucleic acids.

### Claim 15 (depends on 14)

The method of claim 14, wherein the method includes a step of extracting nucleic acids from a biological sample to create the input sample.

### Claim 16 (depends on 15)

The method of claim 15, wherein the biological sample is a bodily fluid of a subject, the bodily fluid selected from the group consisting of mucus, sputum (processed or unprocessed), bronchial alveolar lavage (BAL), bronchial wash (BW), bodily fluids, cerebrospinal fluid (CSF), urine, tissue, rectal swab, nasopharyngeal aspirate, nasopharyngeal swab, throat swab, feces, plasma, serum, and whole blood.

### Claim 17 (depends on 16)

The method of claim 16, wherein the method further comprises a step of obtaining the biological sample from the subject, optionally wherein the subject is selected from the group consisting of a subject who has one or more symptoms of COVID-19, an asymptomatic subject who is at increased risk of being infected with SARS-COV-2 virus, a subject who has received a vaccine against infection with SARS-COV-2 virus, and a deceased subject.

### Claim 18 (depends on 12)

The method of claim 12, wherein the input sample contains 10 or more copies of the SARS-COV-2 N gene.

### Claim 19 (depends on 6, 12)

The method of claim 12 further comprising
(b) contacting the input sample with the composition of claim 6 under conditions sufficient for amplification of one or more regions of the ORF1b gene of SARS-COV-2,
wherein detection the SARS-COV-2 ORF1b gene amplification product indicates the presence of SARS-COV-2 in the input sample.

### Claim 20 (depends on 19)

The method of claim 19, wherein the input sample contains 10 or more copies of the SARS-COV-2 ORF1b gene.